Table 3 OS multivariate analysis on FAS and FAS CORRECT populations
Overall survival | Hazard ratio (95 % CI) | P | Relative weight |
|---|---|---|---|
FAS Population | |||
ECOG Performance Status | <0.001 | ||
0 | 1 | 0 | |
1 | 1.54 (1.26–1.88) | +2 | |
≥ 2 | 3.43 (2.50–4.70) | +4 | |
Time since initial diagnosis | <0.001 | ||
≥ 18 months | 1 | 0 | |
< 18 months | 1.72 (1.40–2.13) | +2 | |
Initial daily dose of regorafenib | 0.042 | ||
160 | 1 | 0 | |
< 160 | 1.26 (1.01–1.57) | +1 | |
Number of metastatic sites | 0.020 | ||
< 3 | 1 | 0 | |
3+ | 1.29 (1.04–1.60) | +1 | |
Liver metastases | <0.001 | ||
No | 1 | 0 | |
Yes | 1.61 (1.29–2.01) | +2 | |
KRAS | 0.016 | ||
Wild-type | 1 | 0 | |
Mutated | 1.25 (1.04–1.49) | +1 | |
FAS CORRECT Population | |||
ECOG Performance Status | 0.001 | ||
0 | 1 | 0 | |
1 | 1.45 (1.16–1.81) | +1 | |
≥ 2 | |||
Time since initial diagnosis | 0.001 | ||
≥ 18 months | 1 | 0 | |
< 18 months | 1.55 (1.21–1.99) | +1 | |
Number of metastatic sites | 0.013 | ||
< 3 | 1 | 0 | |
3+ | 1.38 (1.07–1.77) | +1 | |
Liver metastases | <0.001 | ||
No | 1 | 0 | |
Yes | 1.65 (1.28–2.13) | +1 | |